Charles River Laboratories International (CRL) – Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Charles River Laboratories International (NYSE: CRL) in the last few weeks:

• 7/8/2026 – Charles River Laboratories International had its “buy” rating reaffirmed by Citigroup Inc..
• 7/1/2026 – Charles River Laboratories International was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/1/2026 – Charles River Laboratories International was given a new $250.00 price target by Sanford C. Bernstein.
• 7/1/2026 – Charles River Laboratories International was given a new $250.00 price target by BNP Paribas Exane.
• 6/17/2026 – Charles River Laboratories International was upgraded by Morgan Stanley from “equal weight” to “overweight”. They now have a $220.00 price target on the stock, up from $185.00.
• 6/16/2026 – Charles River Laboratories International was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/29/2026 – Charles River Laboratories International was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/29/2026 – Charles River Laboratories International was upgraded by CLSA from “hold” to “outperform”. They now have a $219.00 price target on the stock, up from $167.00.
• 5/11/2026 – Charles River Laboratories International was downgraded by Weiss Ratings from “sell (d)” to “sell (e+)”.

Insider Activity

In related news, Director James C. Foster sold 75,000 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the transaction, the director owned 31,596 shares in the company, valued at approximately $7,109,100. This represents a 70.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.